

DESCRIPTION


| | |
|---------------------------|--|
| Species Reactivity | Human |
| Specificity | Detects human Serpin E1 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human Serpin A1, A3, A4, A8, C1, F1, F2, I1, I2, recombinant mouse Serpin D1 or E2 is observed. |
| Source | Monoclonal Mouse IgG ₁ Clone # 242816 |
| Purification | Protein A or G purified from hybridoma culture supernatant |
| Immunogen | <i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human Serpin E1/PAI-1 Met1-Pro402 Accession # P05121 |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

| | Recommended Concentration | Sample |
|---|--|--|
| Western Blot | 1 µg/mL | Recombinant Human Serpin E1/PAI-1 (Catalog # 1786-PI) |
| Human Serpin E1/PAI-1 Sandwich Immunoassay | | Reagent |
| ELISA Capture | 2-8 µg/mL | Human Serpin E1/PAI-1 Antibody (Catalog # MAB1786) |
| ELISA Detection Standard | 0.1-0.4 µg/mL | Human Serpin E1/PAI-1 Biotinylated Antibody (Catalog # BAF1786) Recombinant Human Serpin E1/PAI-1 (Catalog # 1786-PI) |
| Neutralization | Measured by its ability to neutralize Recombinant Human Serpin E1/PAI-1 (0.25 µg/mL, Catalog # 1786-PI) inhibition of Recombinant Human u-Plasminogen Activator (uPA)/Urokinase (0.1 µg/mL, Catalog # 1310-SE) cleavage of the fluorogenic peptide substrate Z-GGR-AMC (100 µM). The Neutralization Dose (ND ₅₀) is typically 0.3 µg/mL. | |

DATA



PREPARATION AND STORAGE

| | |
|--------------------------------|--|
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

BACKGROUND

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI-1 is the principal inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI-1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2-4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N-terminal signal peptide (6, 7). PAI-1 may exist in one of two possible conformations, designated as active or latent (8).

References:

1. Silverman, G.A. *et al.* (2001) *J. Biol. Chem.* **276**:33293.
2. Stefansson, S. *et al.* (2003) *Curr. Pharm. Des.* **9**:1545.
3. Duffy, M.J. (2002) *Clin. Chem.* **48**:1194.
4. Juhan-Vague, I. *et al.* (2003) *J. Thromb. Haemost.* **1**:1575.
5. Harbeck, N. *et al.* (2002) *Clin. Breast Cancer* **3**:196.
6. Pannekoek, H. *et al.* (1986) *EMBO J.* **5**:2539.
7. Ginsburg, D. *et al.* (1986) *J. Clin. Invest.* **78**:1673.
8. Wang, Z. *et al.* (1996) *Biochemistry* **35**:16443.
9. Stromqvist, M. *et al.* (1994) *Protein Expr. Purif.* **5**:309.